This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kuznetsov, G. Articles by Littlefield, B. A. Search for Related Content PubMed PubMed Citation Articles by Kuznetsov, G. Articles by Littlefield, B. A.

Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389

Departments of ¹ Candidate Assessment and In Vitro Technologies, ² Life Sciences, ³ Lead Optimization, ⁴ Scientific Administration, and ⁵ Advisory Board, Eisai Research Institute, Andover, Massachusetts, and ⁶ Discovery Research Laboratories II, Tsukuba Research Laboratories, Eisai Company, Ltd., Tsukuba-shi, Ibaraki, Japan

E7389, a macrocyclic ketone analog of the marine natural product halichondrin B, currently is undergoing clinical trials for cancer. This fully synthetic agent exerts its highly potent in vitro and in vivo anticancer effects via tubulin-based antimitotic mechanisms, which are similar or identical to those of parental halichondrin B. In an attempt to understand the impressive potency of E7389 in animal models of human cancer, its ability to induce apoptosis following prolonged mitotic blockage was evaluated. Treatment of U937 human histiocytic lymphoma cells with E7389 led to time-dependent collection of cells in the G₂-M phase of the cell cycle, beginning as early as 2 h and becoming maximal by 12 h. Increased numbers of hypodiploid events were seen beginning at 12 h, suggesting initiation of apoptosis after prolonged E7389-induced mitotic blockage. The identity of hypodiploid events as apoptotic cells under these conditions was confirmed by two additional morphologic criteria: green to orange/yellow shifts on acridine orange/ethidium bromide staining, and cell surface annexin V binding as assessed by flow cytometry. Several biochemical correlates of apoptosis also were seen following E7389 treatment, including phosphorylation of the antiapoptotic protein Bcl-2, cytochrome c release from mitochondria, proteolytic activation of caspase-3 and -9, and cleavage of the caspase-3 substrate poly(ADP-ribose) polymerase (PARP). In LNCaP human prostate cancer cells, treatment with E7389 also led to generation of hypodiploid cells, activation of caspase-3 and -9, and appearance of cleaved PARP, indicating that E7389 can activate cellular apoptosis pathways under anchorage-independent and -dependent cell culture conditions. These results show that prolonged mitotic blockage by E7389 can lead to apoptotic cell death of human cancer cells in vitro and can provide a mechanistic basis for the significant in vivo anticancer efficacy of E7389.

This article has been cited by other articles:

				T. Okouneva, O. Azarenko, L. Wilson, B. A. Littlefield, and M. A. Jordan Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase Mol. Cancer Ther., July 1, 2008; 7(7): 2003 - 2011. [Abstract] [Full Text] [PDF]

				D. A. Dabydeen, J. C. Burnett, R. Bai, P. Verdier-Pinard, S. J. H. Hickford, G. R. Pettit, J. W. Blunt, M. H. G. Munro, R. Gussio, and E. Hamel Comparison of the Activities of the Truncated Halichondrin B Analog NSC 707389 (E7389) with Those of the Parent Compound and a Proposed Binding Site on Tubulin Mol. Pharmacol., December 1, 2006; 70(6): 1866 - 1875. [Abstract] [Full Text] [PDF]

				M. A. Jordan, K. Kamath, T. Manna, T. Okouneva, H. P. Miller, C. Davis, B. A. Littlefield, and L. Wilson The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth Mol. Cancer Ther., July 1, 2005; 4(7): 1086 - 1095. [Abstract] [Full Text] [PDF]

				Z. N. Demidenko, D. Halicka, J. Kunicki, J. A. McCubrey, Z. Darzynkiewicz, and M. V. Blagosklonny Selective Killing of Adriamycin-Resistant (G2 Checkpoint-Deficient and MRP1-Expressing) Cancer Cells by Docetaxel Cancer Res., May 15, 2005; 65(10): 4401 - 4407. [Abstract] [Full Text] [PDF]